NCT02742779View on ClinicalTrials.gov

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 15, 2015

Primary Completion Date

June 7, 2017

Study Completion Date

June 7, 2017

Conditions
Healthy Volunteer
Interventions
DRUG

GDC-0310

Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.

DRUG

Placebo

Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.

Trial Locations (1)

84106

PRA Health Sciences, Salt Lake City

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT02742779 - A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers | Biotech Hunter | Biotech Hunter